Moderna announces progress in prophylactic vaccines modality with CMV Vaccine phase 2 study data now expected in third quarter 2020

This article was originally published here

The Company also announced three new vaccine development candidates, which support the Company’s strategy, announced January 12, to accelerate new development candidates in its core modalities, prophylactic vaccines

The post Moderna announces progress in prophylactic vaccines modality with CMV Vaccine phase 2 study data now expected in third quarter 2020 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply